ReviewThe lancet. HIV2023
Long-acting antiretrovirals and HIV treatment adherence.
Review in The lancet. HIV, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- The association between disclosure and antiretroviral therapy among adults living with HIV in China: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2025Pooled it
- Better Longitudinal Adherence to Antiretroviral Therapy Among Virally Suppressed People With HIV Is Associated With Reduced Occurrence of Serious Non-AIDS Events.Open forum infectious diseases · 2026Trial
- The Acceptability of a Real-Time Medication Monitoring-Based Digital Adherence Tool Among Young People Living with HIV in Malawi.AIDS and behavior · 2026Trial
- Trial
- Mortality and Loss to Follow-Up Among Adolescents and Young Adults Attending HIV Care Programs in Kenya.AIDS patient care and STDs · 2023Trial
- Epidemiologic Impact of Prioritizing Long-Acting Injectable Cabotegravir to Men Who Have Sex With Men With Low Pre-Exposure Prophylaxis Use Adherence in the Netherlands: A Mathematical Modeling Study.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Hepatitis B virus outcomes in people with HIV after cessation of tenofovir-containing antiretroviral therapy: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Factors Associated with ART Adherence and Sustained Viral Suppression Among US Young Adults with HIV, 2015-2022.AIDS and behavior · 2026Article
- Heterogeneity of patient preferences for long-acting HIV treatment among people with HIV in Kenya.BMC infectious diseases · 2026Article
- Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.AIDS (London, England) · 2026Article
- Latin America and the Caribbean: Challenges and Opportunities for HIV Treatment and Prevention.Journal of the International AIDS Society · 2026Article
- Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies.bioRxiv : the preprint server for biology · 2026Article
- Enhancing therapy monitoring and effectiveness for HIV patients in China's border regions through a healthcare consortium: an interrupted time series analysis.BMC infectious diseases · 2026Article
- Long-Acting Injectable Antiretroviral Therapy in Medicare-Enrolled Adults With HIV.JAMA network open · 2026Article
- Combined injectable regimens in treatment-experienced HIV/AIDS patients at a southern academic medical center: a case series.BMC infectious diseases · 2026Article
- Perinatal outcomes associated with antiretroviral therapy for pregnant women living with HIV: an umbrella review.EClinicalMedicine · 2026Review
- Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access.Clinical pharmacology and therapeutics · 2026Article
- A White Paper on Advancing Long-Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation.Clinical pharmacology and therapeutics · 2026Review
- A Scoping Review Assessing the Relationship Between Structural, Functional, and Perceived Social Support with Antiretroviral Therapy (ART) in the Last Decade.AIDS and behavior · 2026Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 9 institutions in 3 countries.
Funding
Abstract
Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV. Long-acting cabotegravir with rilpivirine ART has reduced required dosing frequency from once daily to once every month or every 2 months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment. Although long-acting ART has high potential to be revolutionary in the landscape of HIV care, prevention, and treatment cascade, more data are needed to substantiate its efficacy and cost-effectiveness among patients at risk of non-adherence and across age groups, pregnancy, and post partum. Advocacy efforts and policy changes to optimise a sustained, high-quality, equitable reach of long-acting ART, especially in low-income and middle-income countries where most people living with HIV reside, are needed to realise the full benefits of long-acting ART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.